The Big Pharma

See the following -

TransCelerate Shares Its Take On Risk-Based Monitoring Models And Tech

Nick Paul Taylor | Fierce BioTech IT | September 20, 2014

With clinical trial sponsors spending a sizable chunk of their huge Phase III trial budgets on source data verification (SDV) in return for questionable benefits, risk-based monitoring is an obvious target for TransCelerate BioPharma's R&D efficiency agenda. The Big Pharma consortium has further clarified its thinking on the topic in two research papers...

Read More »